Metaxa Cancer Center Hospital Of Piraeus
- Address
- lock Available on a paid plan
Metaxa Cancer Center Hospital Of Piraeus
Metaxa Cancer Center Hospital Of Piraeus is a distinguished oncology research institution in Greece, specializing in advanced clinical trials across multiple cancer types. The center demonstrates particular expertise in hematologic malignancies and solid tumor oncology, with a strong focus on innovative combination therapies and targeted treatment approaches.
- Multiple Myeloma and Plasma Cell Disorders: Conducting cutting-edge trials evaluating novel antibody-based combinations, particularly in newly diagnosed patients with renal impairment and primary plasma cell leukemia
- Lung Cancer Research: Participating in phase 2 and 3 studies investigating immunotherapy combinations, HER2-targeted therapies, and PARP inhibitor maintenance strategies for non-small cell lung cancer
- Breast Cancer Innovation: Exploring advanced treatment regimens including HER2-targeted antibody-drug conjugates, endocrine therapy combinations, and next-generation hormone receptor modulators for metastatic disease
- Inflammatory Bowel Disease: Contributing to gastrointestinal research through dual-targeted therapy trials for moderately to severely active Crohn's disease
The center's research portfolio reflects a commitment to addressing complex patient populations, including those with severe organ impairment and previously treated advanced malignancies. Their participation in international multicenter trials and Greek collaborative study groups positions them as a key contributor to advancing precision medicine and combination immunotherapy approaches in oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 61 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 61 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Merck Sharp & Dohme LLC3active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Metaxa Cancer Center Hospital Of Piraeus
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Janssen Cilag International | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 61 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2020-12-18 | 2026-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.